Cannabidiol—recent advances
Abstract
The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cannabidiol's antinociceptive effects have been attributed to inhibition of anandamide degradation, antioxidant properties, or binding to an unknown cannabinoid receptor.
“CBD's antinociceptive effects have additionally been attributed to inhibition of anandamide degradation, the compound's antioxidant properties, or binding to an unknown cannabinoid receptor.144”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [144]
Cannabidiol has very low affinity for cannabinoid CB1 and CB2 receptors.
“Cannabidiol is a natural constituent in cannabis, which has very low affinity for cannabinoid CB1 and CB2 receptors.”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [144]
Cannabidiol may compete with cannabinoid agonists for cannabinoid receptor binding sites, thereby minimizing psychoactivity of drugs that employ a combination of Δ9-THC and cannabidiol.
“CBD may compete with cannabinoid agonists for cannabinoid receptor binding sites, thereby minimizing psychoactivity of drugs that employ a combination of Δ9-THC and CBD.”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [144]
Cannabidiol may act as a high potency antagonist of cannabinoid agonists and an inverse agonist at CB2 receptors.
“It may act as a high potency antagonist of cannabinoid agonists and an inverse agonist at CB2 receptors.144”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [144]
Cannabidiol acts as an agonist at serotonin 5-HT1a receptors.
“CBD also acts as an agonist at serotonin 5-HT1a receptors.144”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [144]
Cites
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,079 · see citing works
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · see citing works
Cannabidiol and (−)Δ <sup>9</sup> -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · see citing works
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669 · see citing works
Russo, E. B., & Guy, G. W. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 608 · see citing works
Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., PETROCELLIS, L. D., Laezza, C., Portella, G., Bifulco, M., & Marzo, V. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 569 · see citing works
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 511 · see citing works
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · see citing works
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407 · see citing works
Self-citationCannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 379 · see citing works
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361 · see citing works
García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Nicholson, A. N., Turner, C., Stone, B. M., & Robson, P. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125688.05091.8f · Cited by 291 · see citing works
Hypnotic and Antiepileptic Effects of Cannabidiol
Carlini, E. A., & Cunha, J. M. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02622.x · Cited by 278 · see citing works
Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
El‐Remessy, A. B., Al‐Shabrawey, M., Khalifa, Y. M., Tsai, N., Caldwell, R. B., & Liou, G. I. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050500 · Cited by 275 · see citing works
Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061002 · Cited by 272 · see citing works
Esposito, G., Filippis, D. D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252 · see citing works
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
Mechoulam, R., & Hanuš, L. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00144-5 · Cited by 250 · see citing works
Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225 · see citing works
Mishima, K., Hayakawa, K., Abe, K., Ikeda, T., Egashira, N., Iwasaki, K., & Fujiwara, M. (2005) · Stroke · doi:10.1161/01.str.0000163083.59201.34 · Cited by 225 · see citing works
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., & Gallily, R. (2005) · Autoimmunity · doi:10.1080/08916930500356674 · Cited by 216 · see citing works
McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P. S., & Nagarkatti, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023937 · Cited by 211 · see citing works
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., & Parolaro, D. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6156-x · Cited by 197 · see citing works
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192 · see citing works
Hamelink, C., Hampson, A. J., Wink, D. A., Eiden, L. E., & Eskay, R. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085779 · Cited by 190 · see citing works
Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells
Srivastava, M. D., Srivastava, B. I. S., & Brouhard, B. H. (1998) · Immunopharmacology · doi:10.1016/s0162-3109(98)00041-1 · Cited by 189 · see citing works
Kim‐Mitsuyama, S., Yamamoto, E., Tanaka, T., Zhan, Y., Izumi, Y., Izumiya, Y., Ioroi, T., Wanibuchi, H., & Iwao, H. (2005) · Stroke · doi:10.1161/01.str.0000163084.16505.e3 · Cited by 173 · see citing works
Parker, L. A., Burton, P., Sorge, R. E., Yakiwchuk, C., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1825-7 · Cited by 171 · see citing works
The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells
Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., & Arnold, J. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.033 · Cited by 157 · see citing works
Pertwee, R. G., Ross, R. A., Craib, S. J., & Thomas, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02624-9 · Cited by 156 · see citing works
Vaccani, A., Massi, P., Colombo, A., Rubino, T., & Parolaro, D. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706134 · Cited by 154 · see citing works
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew)
Parker, L. A., Kwiatkowska, M., Burton, P., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1571-2 · Cited by 146 · see citing works
Sumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134 · see citing works
Analgesic and antiinflammatory activity of constituents ofCannabis sativa L.
Formukong, E. A., EVANS, A. T., & Evans, F. J. (1988) · Inflammation · doi:10.1007/bf00915771 · Cited by 130 · see citing works
Sacerdote, P., Martucci, C., Vaccani, A., Bariselli, F., Panerai, A. E., Colombo, A., Parolaro, D., & Massi, P. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.003 · Cited by 126 · see citing works
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
Murillo‐Rodríguez, E., Millán‐Aldaco, D., Palomero‐Rivero, M., Mechoulam, R., & Drucker-Colı́n, R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.102 · Cited by 116 · see citing works
Watzl, B., Scuderi, P., & WATSON, R. R. (1991) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(91)90160-9 · Cited by 111 · see citing works
Ben‐Shabat, S., Hanuš, L. O., Katzavian, G., & Gallily, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050709m · Cited by 106 · see citing works
Effeets of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns
Feinberg, I., Jones, R. T., Walker, J. M., Cavness, C., & Floyd, T. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976196782 · Cited by 104 · see citing works
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors
Hanu, L. O., Tchilibon, S., Ponde, D. E., Breuer, A., Fride, E., & Mechoulam, R. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b416943c · Cited by 103 · see citing works
Malone, D. T., & TAYLOR, D. A. H. B. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702753 · Cited by 97 · see citing works
Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability
Jacobsson, S. O. P., Rongård, E., Stridh, M., Tiger, G., & Fowler, C. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00492-5 · Cited by 94 · see citing works
Trost, B. M., & Dogra, K. (2007) · Organic Letters · doi:10.1021/ol063022k · Cited by 92 · see citing works
Hayakawa, K., Mishima, K., Nozako, M., Ogata, A., Hazekawa, M., Liu, A.-X., Fujioka, M., Abe, K., Hasebe, N., Egashira, N., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.005 · Cited by 89 · see citing works
Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
Eshhar, N., Striem, S., Kohen, R., Tirosh, O., & Biegon, A. R. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00271-l · Cited by 85 · see citing works
Hypnoticlike effects of cannabidiol in the rat
Monti, J. M. (1977) · Psychopharmacology · doi:10.1007/bf00497858 · Cited by 84 · see citing works
Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes
Kaplan, B. L. F., Rockwell, C. E., & Kaminski, N. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051961 · Cited by 81 · see citing works
6ʺ-Azidohex-2ʺ-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist
Thomas, A., Ross, R. A., Saha, B., Mahadevan, A., Razdan, R. K., & Pertwee, R. G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.023 · Cited by 76 · see citing works
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
Guimaraes, V. H. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.015 · Cited by 75 · see citing works
Braida, D., Pegorini, S., Arcidiacono, M. V., Consalez, G. G., Croci, L., & Sala, M. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00569-x · Cited by 73 · see citing works
Boron triflouride etherate on alimina - a modified Lewis acid reagent.
Baek, S., Srebnik, M., & Mechoulam, R. (1985) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)98518-6 · Cited by 71 · see citing works
A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells
Kogan, N. M., Blázquez, C., Álvarez, L., Gallily, R., Schlesinger, M., Guzmán, M., & Mechoulam, R. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021089 · Cited by 70 · see citing works
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., & Mechoulam, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0039 · Cited by 68 · see citing works
PARKER, L., KWIATKOWSKA, M., & Mechoulam, R. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.08.045 · Cited by 67 · see citing works
Mannila, J., Järvinen, T., Järvinen, K., & Jarho, P. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20766 · Cited by 66 · see citing works
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only
Fride, E., Feigin, C., Ponde, D. E., Breuer, A., Hanuš, L., Arshavsky, N., & Mechoulam, R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.049 · Cited by 62 · see citing works
Gallily, R., Even-Chen, T., Katzavian, G., Lehmann, D., Dagan, A., & Mechoulam, R. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000103917 · Cited by 62 · see citing works
Pharmacological and therapeutic targets for Δ9 tetrahydrocannabinol and cannabidiol
Pertwee, R. G. (2004) · Euphytica · doi:10.1007/s10681-004-4756-9 · Cited by 57 · see citing works
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism
Hayakawa, K., Mishima, K., Abe, K., Hasebe, N., Takamatsu, F., Yasuda, H., Ikeda, T., Inui, K., Egashira, N., Iwasaki, K., et al. (2004) · Neuroreport · doi:10.1097/00001756-200410250-00016 · Cited by 56 · see citing works
Synthesis of Cannabidiols via Alkenylation of Cyclohexenyl Monoacetate
Kobayashi, Y., Takeuchi, A., & Wang, Y. (2006) · Organic Letters · doi:10.1021/ol060692h · Cited by 51 · see citing works
Synthesis of a Primary Metabolite of Cannabidiol
Tchilibon, S., & Mechoulam, R. (2000) · Organic Letters · doi:10.1021/ol006369a · Cited by 40 · see citing works
The pharmacological actions of cannabidiol
Long, L. E., Malone, D. T., & TAYLOR, D. A. H. B. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.07.915908 · Cited by 20 · see citing works
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
Guimaraes, V. H. (2004) · Life Sciences · doi:10.1016/s0024-3205(04)00291-7 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535 · see citing works
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · see citing works
Cannabidiol is a negative allosteric modulator of the cannabinoid CB <sub>1</sub> receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · see citing works
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 851 · see citing works
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 718 · see citing works
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680 · see citing works
McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 526 · see citing works
Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A. S., Ross, S. A., Khan, I. A., & ElSohly, M. A. (2010) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2010.01441.x · Cited by 475 · see citing works
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 484 · see citing works
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 479 · see citing works
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_4 · Cited by 488 · see citing works
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Foll, B. L., Hall, W., Rehm, J. T., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 436 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 402 · see citing works
Phytocannabinoids: Origins and Biosynthesis
Gülck, T., & Møller, B. L. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2020.05.005 · Cited by 393 · see citing works
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 392 · see citing works
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366 · see citing works
Fernández‐Ruíz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R. G., Mechoulam, R., & Martínez-Orgado, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 356 · see citing works
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324 · see citing works
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14440 · Cited by 321 · see citing works
Crane, N. A., Schuster, R. M., Fusar‐Poli, P., & González, R. (2012) · Neuropsychology Review · doi:10.1007/s11065-012-9222-1 · Cited by 310 · see citing works
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · see citing works
Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 302 · see citing works
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285 · see citing works
Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., & Vogel, Z. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.069294 · Cited by 286 · see citing works
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279 · see citing works
Best Practice & Research Clinical Endocrinology & Metabolism
Grieb, M. (2009) · Cited by 276 · see citing works
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272 · see citing works
de Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 264 · see citing works
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels
Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 258 · see citing works
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255 · see citing works
Self-citationPositive and Negative Effects of Cannabis and Cannabinoids on Health
Cohen, K., Weizman, A., & Weinstein, A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1381 · Cited by 255 · see citing works
Pan, H., Mukhopadhyay, P., Rajesh, M., Patel, V., Mukhopadhyay, B., Gao, B., Haskó, G., & Pacher, P. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147181 · Cited by 256 · see citing works
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 256 · see citing works
Nabissi, M., Morelli, M. B., Santoni, M., & Santoni, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs328 · Cited by 248 · see citing works
Booz, G. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.007 · Cited by 246 · see citing works
Molecular Pharmacology of Phytocannabinoids
Turner, S. E., Williams, C. M., Iversen, L. L., & Whalley, B. J. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_3 · Cited by 246 · see citing works
Gloss, D. S., & Vickrey, B. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009270.pub3 · Cited by 239 · see citing works
Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation
Rom, S., & Persidsky, Y. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9445-9 · Cited by 241 · see citing works
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 236 · see citing works
The endocannabinoid system in anxiety, fear memory and habituation
Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408958 · Cited by 236 · see citing works
Cannabinoids and Cannabinoid Receptors: The Story so Far
Shahbazi, F., Grandi, V., Banerjee, A., & Trant, J. F. (2020) · iScience · doi:10.1016/j.isci.2020.101301 · Cited by 234 · see citing works
Pazos, M. R., Mohammed, N., Lafuente, H., Santos, M., Martínez‐Pinilla, E., Moreno, E., Valdizán, E. M., Romero, J., Pazos, Á., Franco, R., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.027 · Cited by 223 · see citing works
Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I., Benjaminov, F., & Konikoff, F. M. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4540-z · Cited by 216 · see citing works
Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208 · see citing works
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Izzo, A. A., & Camilleri, M. (2008) · Gut · doi:10.1136/gut.2008.148791 · Cited by 197 · see citing works
Cohen, K., & Weinstein, A. M. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00162 · Cited by 197 · see citing works
Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben‐Nun, A., Juknat, A., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01379.x · Cited by 193 · see citing works
Borrelli, F., Aviello, G., Romano, B., Orlando, P., Capasso, R., Maiello, F., Guadagno, F., Petrosino, S., Capasso, F., Marzo, V. D., et al. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0512-x · Cited by 189 · see citing works
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol
Morales, P., Reggio, P. H., & Jagerovic, N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00422 · Cited by 181 · see citing works
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 182 · see citing works
Maione, S., Piscitelli, F., Gatta, L., Vita, D. D., PETROCELLIS, L. D., Palazzo, E., de Novellis, V., & Marzo, V. D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 176 · see citing works
Gallily, R., Yekhtin, Z., & Hanuš, L. O. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.62010 · Cited by 169 · see citing works
Pereira, M. D. S., Guimarães, F. S., Del‐Bel, E., Raisman‐Vozari, R., & Michel, P. P. (2019) · Glia · doi:10.1002/glia.23738 · Cited by 169 · see citing works
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 167 · see citing works
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., & Haeseler, G. (2009) · Pharmacology · doi:10.1159/000201556 · Cited by 154 · see citing works
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
Schier, A. R. D. M., Ribeiro, N. P. D. O., Silva, A. C. D. O. E., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462012000500008 · Cited by 154 · see citing works
Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · see citing works
Alvarez, F. J., Lafuente, H., Rey-Santano, M. C., Mielgo, V., Gastiasoro, E., Rueda, M. A., Pertwee, R. G., Castillo, A. I., Romero, J., & Martínez-Orgado, J. A. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e318186e5dd · Cited by 151 · see citing works
Pazos, M. R., Cinquina, V., Gómez, A., Layunta, R., Santos, M., Fernández‐Ruíz, J., & Martínez-Orgado, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.034 · Cited by 151 · see citing works
Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., & Frey, W. H. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-16 · Cited by 151 · see citing works
Cannabis, cannabidiol, and epilepsy — From receptors to clinical response
Szaflarski, J. P., & Bebin, E. M. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.08.135 · Cited by 150 · see citing works
Molecular and Cellular Mechanisms of Action of Cannabidiol
Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. A. (2023) · Molecules · doi:10.3390/molecules28165980 · Cited by 158 · see citing works
Sangiovanni, E., Fumagalli, M., Pacchetti, B., Piazza, S., Magnavacca, A., Khalilpour, S., Melzi, G., Martinelli, G., & Dell’Agli, M. (2019) · Phytotherapy Research · doi:10.1002/ptr.6400 · Cited by 149 · see citing works
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 148 · see citing works
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., & Denovan‐Wright, E. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557025 · Cited by 141 · see citing works
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140 · see citing works
The emerging role of the endocannabinoid system in cardiovascular disease
Pacher, P., & Steffens, S. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0145-8 · Cited by 139 · see citing works
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136 · see citing works
Bacterial terpene biosynthesis: challenges and opportunities for pathway engineering
Helfrich, E. J. N., Lin, G.-M., Voigt, C. A., & Clardy, J. (2019) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.15.283 · Cited by 136 · see citing works
Hassan, S., Eldeeb, K., Millns, P. J., Bennett, A. J., Alexander, S. P. H., & Kendall, D. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12615 · Cited by 135 · see citing works
Kis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148 · see citing works
Ward, S. J., Ramirez, M. D., Neelakantan, H., & Walker, E. A. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3182283486 · Cited by 133 · see citing works
Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
Han, S., Thatte, J., Buzard, D. J., & Jones, R. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005626 · Cited by 134 · see citing works
Katsidoni, V., Anagnostou, I., & Panagis, G. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00483.x · Cited by 132 · see citing works
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131 · see citing works
Cohen, K., & Weinstein, A. M. (2018) · Brain Sciences · doi:10.3390/brainsci8030040 · Cited by 129 · see citing works
Baldino, L., Scognamiglio, M., & Reverchon, E. (2020) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2020.104960 · Cited by 129 · see citing works
Manini, A. F., Yiannoulos, G., Bergamaschi, M. M., Hernandez, S. H., Olmedo, R., Barnes, A. J., Winkel, G. H., Sinha, R., Jutras‐Aswad, D., Huestis, M. A., et al. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000118 · Cited by 127 · see citing works
Hegde, V. L., Nagarkatti, P. S., & Nagarkatti, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018281 · Cited by 126 · see citing works
Cannabinoid-induced changes in respiration of brain mitochondria
Fišar, Z., Singh, N., & Hroudová, J. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.09.002 · Cited by 123 · see citing works
Interplay between chemistry and morphology in medical cannabis (Cannabis sativa L.)
Bernstein, N., Gorelick, J., & Koch, S. (2018) · Industrial Crops and Products · doi:10.1016/j.indcrop.2018.11.039 · Cited by 120 · see citing works
Ruiz‐Valdepeñas, L., Martínez-Orgado, J. A., Benito, C., Millán‐Uclés, Á., Tolón, R. M., & Romero, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-5 · Cited by 119 · see citing works
Cannabidiol, extracted fromCannabis sativa, selectively inhibits inflammatory hypermotility in mice
Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F., & Izzo, A. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.177 · Cited by 120 · see citing works
Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors
Ignatowska-Jankowska, B. M., Jankowski, M. M., & Swiergiel, A. H. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.12.031 · Cited by 119 · see citing works
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 121 · see citing works
Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Gao, F., Coppola, G., Geschwind, D. H., & Vogel, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061462 · Cited by 117 · see citing works
de la Ossa, D. H. P., Ligresti, A., Gil-Alegre, M. E., Aberturas, M. R., Molpeceres, J., Marzo, V. D., & Torres‐Suárez, A. I. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.003 · Cited by 116 · see citing works
Kogan, N. M., Melamed, E., Wasserman, E., Raphael-Mizrahi, B., Breuer, A., Stok, K. S., Sondergaard, R. E., Escudero, A. V. V., Baraghithy, S., Attar-Namdar, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2513 · Cited by 115 · see citing works
Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
Marzo, V. D., Piscitelli, F., & Mechoulam, R. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_4 · Cited by 114 · see citing works
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · see citing works
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence
Jensen, B., Chen, J. L., Furnish, T. J., & Wallace, M. S. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0524-x · Cited by 111 · see citing works
Terpenoids with Special Pharmacological Significance: A Review
Jaeger, R., & Cuny, E. (2016) · Natural Product Communications · doi:10.1177/1934578x1601100946 · Cited by 110 · see citing works
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.021 · Cited by 111 · see citing works
Yamada, T., Ueda, T., Shibata, Y., Ikegami, Y., Saito, M., Ishida, Y., Ugawa, S., Kohri, K., & Shimada, S. (2010) · Urology · doi:10.1016/j.urology.2010.03.029 · Cited by 108 · see citing works
Lim, M. P., Devi, L. A., & Rozenfeld, R. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.52 · Cited by 108 · see citing works
Morelli, M. B., Offidani, M., Alesiani, F., Discepoli, G., Liberati, S., Olivieri, A., Santoni, M., Santoni, G., Leoni, P., & Nabissi, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28591 · Cited by 107 · see citing works
Raj, V., Park, J. G., Cho, K.-H., Choi, P., Kim, T., Ham, J., & Lee, J. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.12.020 · Cited by 106 · see citing works
The role of the CB1 receptor in the regulation of sleep
Murillo‐Rodríguez, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.04.008 · Cited by 107 · see citing works
- Authors
- Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Corresponding author
- Mechoulam, Raphael
- Venue
- Chemistry & Biodiversity
- Publisher
- Wiley
- Published
- 2007-08
- Volume
- 4
- Issue
- 8
- Pages
- 1678-1692
- ISSN
- 1612-1872 (ISSN-L)
- 1612-1880
- OpenAlex
- W2065788111
- Cited by
- 515
- References
- 65
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 25 · 2023: 29 · 2022: 28 · 2021: 38 · 2020: 46 · 2019: 33 · 2018: 30 · 2017: 26 · 2016: 20 · 2015: 25 · 2014: 34 · 2013: 26 · 2012: 26
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemistry & Biodiversity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cannabidiol, cannabis, non-psychoactive cannabinoids
- MeSH terms
- Animals, Antioxidants, Cannabidiol, Brain Ischemia, Humans, Neoplasms, Receptors, Opioid, Neuroprotective Agents, Receptor, Serotonin, 5-HT1A, Cannabinoid Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
